We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TDAC:NASDAQTranslational Development Acquisition Corp. Analysis

Data as of 2026-06-11 - not real-time

$10.74

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

TDAC is trading at $10.74, comfortably above its 20‑day ($10.70), 50‑day ($10.66) and 200‑day ($10.51) simple moving averages, indicating a short‑term bullish bias. The RSI of 62 reinforces momentum while the MACD histogram is marginally negative, suggesting a near‑term pull‑back risk. Technicals show low volatility (3% 30‑day) and an almost zero beta (0.01), implying limited market‑wide price swings.
Fundamentally, the SPAC has no operating revenue, negative book value, and a high trailing P/E of 38 versus the industry average of 16, flagging an overvalued status. The only catalyst is the announced $3.8 billion merger with ProLogium, a solid‑state battery leader, slated to close in H2 2026, which could convert the shell into a growth‑oriented tech company. Until that transaction finalizes, the stock faces high liquidity risk (daily volume ~5,800 vs 10‑day average >220,000) and a modest cash position against sizable debt, with no dividend sustainability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Pending merger adds upside but also execution uncertainty
  • Bullish technical positioning but MACD hints at near‑term weakness
  • Severe liquidity constraints

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Completion of $3.8 B ProLogium combination unlocks operating business
  • Exposure to high‑growth solid‑state battery market
  • Potential re‑rating of valuation post‑merger

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term secular demand for advanced battery technology
  • Improved fundamentals expected after merger integration
  • Current market price offers upside relative to post‑deal fair value

Key Metrics & Analysis

Financial Health

P/E Ratio38.4
ROA-0.31%
P/B Ratio-7.3
Op. Cash Flow$-681970
Free Cash Flow$-352611
Industry P/E16.5

Technical Analysis

TrendBullish
RSI62.4
Support$10.64
Resistance$10.80
MA 20$10.70
MA 50$10.66
MA 200$10.51
MACDBearish
VolumeDecreasing
Fear & Greed Index82.54

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.01
Volatility3.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.